Replies to post #143351 on Biotech Values

[DewDiligence]

Here are the “vs Humira” Orencia and Actemra PR’s from BMY and Roche, respectively:

http://finance.yahoo.com/news/orencia-abatacept-demonstrates-comparable-efficacy-040100049.html (Orencia)

http://finance.yahoo.com/news/genentech-actemra-improved-rheumatoid-arthritis-220100625.html (Actemra)

I doubt that either of these results will make a dent in Humira’s sales.